|
Glenmark has announced the upcoming launch of eribulin mesylate injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. Glenmark’s eribulin mesylate injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL), of Eisai, Inc., and the company will begin distribution in September 2025.
According to IQVIA sales data for the 12-month period ending July 2025, the Halaven injection, 1 mg/2 mL (0.5 mg/mL) market3 achieved annual sales of approximately $66.3 million.
Commenting on the launch, Marc Kikuchi, president & business head, North America said, “We are pleased to announce the launch of eribulin mesylate injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. As the first complex generic in our portfolio, this launch marks both our commitment to growing our portfolio of products within the institutional channel and reinforces our dedication to bring quality and affordable alternatives to market for patients in need.”
Glenmark’s eribulin mesylate injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is only approved for the indication(s) listed in Glenmark’s approved label. All brand names and trademarks are the property of their respective owners.
Market includes brand and all available therapeutic equivalents. Notea: IQVIA data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.
Glenmark Pharmaceuticals Ltd. is a research-led, global pharmaceutical company, having a presence across branded, generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.
|